Antibody-mediated rejection after liver transplantation is an under-recognised cause of
allograft injury. While definitions of acute and chronic antibody-mediated rejection have …

Methods Using the United Network for Organ Sharing database, we performed primary
analysis on annual waitlist additions and LT surgery trends in patients for the 3 leading …

Hepatitis C virus (HCV) is a global health concern associated with significant morbidity and
mortality. Before the approval of second-generation direct-acting antiviral agents (DAAs) …

Direct‐acting antiviral (DAA) therapy has altered the frequency and outcome of liver
transplantation (LT) for hepatitis C virus (HCV). The high efficacy and tolerability of DAA …

Highly effective direct‐acting antiviral (DAA) therapy has transformed outcomes of liver
transplantation in hepatitis C virus (HCV) patients. We examined longer‐term outcomes in …

Given the scarcity of donated organs and the frequency of death on the waiting list,
strategies that could improve the available supply of high‐quality liver grafts are much …

Background Hepatitis C virus (HCV) cirrhosis is the leading indication for liver
transplantation in the United States, although nonalcoholic steatohepatitis (NASH) is on the …

Background In the United States, alcoholic liver disease (ALD) has recently become the
leading indication for liver transplantation. Methods Using the United Network for Organ …

Introduction and objectives The success of direct-acting antivirals (DAA) has transformed the
management of hepatitis C virus (HCV) infection and has led to the expansion of the …

Background. Liver transplantation (LT) from hepatitis C virus (HCV)− positive donors
[antibody positive (Ab+) or nucleic acid test− positive (NAT+) donors] has been reported to …